248 related articles for article (PubMed ID: 26832408)
1. Drosophila Lung Cancer Models Identify Trametinib plus Statin as Candidate Therapeutic.
Levine BD; Cagan RL
Cell Rep; 2016 Feb; 14(6):1477-1487. PubMed ID: 26832408
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy.
Yang Z; Su Z; DeWitt JP; Xie L; Chen Y; Li X; Han L; Li D; Xia J; Zhang Y; Yang Y; Jin C; Zhang J; Li S; Li K; Zhang Z; Qu X; He Z; Chen Y; Shen Y; Ren M; Yuan Z
EBioMedicine; 2017 May; 19():49-59. PubMed ID: 28454732
[TBL] [Abstract][Full Text] [Related]
3. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
5. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
6. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
8. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Morikawa-Futamatsu K; Adachi S; Maejima Y; Tamamori-Adachi M; Suzuki J; Kitajima S; Ito H; Isobe M
Life Sci; 2006 Aug; 79(14):1380-90. PubMed ID: 16712874
[TBL] [Abstract][Full Text] [Related]
10. Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation.
Sassano A; Altman JK; Gordon LI; Platanias LC
Leuk Lymphoma; 2012 Sep; 53(9):1779-84. PubMed ID: 22356114
[TBL] [Abstract][Full Text] [Related]
11. [Fluvastatin induces apoptosis on human tongue carcinoma cell line HSC-3].
Fujiwara K; Tsubaki M; Yamazoe Y; Nishiura S; Kawaguchi T; Ogaki M; Nishinobo M; Shimamoto K; Moriyama K; Nishida S
Yakugaku Zasshi; 2008 Jan; 128(1):153-8. PubMed ID: 18176067
[TBL] [Abstract][Full Text] [Related]
12. An EGFR-Induced
Bossen J; Uliczka K; Steen L; Pfefferkorn R; Mai MM; Burkhardt L; Spohn M; Bruchhaus I; Fink C; Heine H; Roeder T
Mol Cancer Ther; 2019 Sep; 18(9):1659-1668. PubMed ID: 31217165
[TBL] [Abstract][Full Text] [Related]
13. Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airway-tumour-stroma lung cancer model.
Mas C; Boda B; CaulFuty M; Huang S; Wiszniewski L; Constant S
J Biotechnol; 2015 Jul; 205():111-9. PubMed ID: 25615947
[TBL] [Abstract][Full Text] [Related]
14. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
16. Trametinib (GSK1120212).
Zeiser R; Andrlová H; Meiss F
Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
[TBL] [Abstract][Full Text] [Related]
17. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.
Goard CA; Chan-Seng-Yue M; Mullen PJ; Quiroga AD; Wasylishen AR; Clendening JW; Sendorek DH; Haider S; Lehner R; Boutros PC; Penn LZ
Breast Cancer Res Treat; 2014 Jan; 143(2):301-12. PubMed ID: 24337703
[TBL] [Abstract][Full Text] [Related]
18. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
[TBL] [Abstract][Full Text] [Related]
19. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia.
Calabro A; Tai J; Allen SL; Budman DR
Anticancer Drugs; 2008 Aug; 19(7):705-12. PubMed ID: 18594212
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
Cheng Y; Zheng H; Wang B; Xu W; Xu J; Zhu Y
Dig Liver Dis; 2018 Apr; 50(4):381-388. PubMed ID: 29373239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
